Abstracts the irreversible model. The expression levels of the genes belonging to the cluster were low in normal kidney and increased along with disease peaked at day 14, and the up-regulation was more pronounced in the irreversible model than the reversible model. This cluster included collagen type1, laminin, osteopontin, kidney injury molecule-1 (KIM-1), and thymosin b10. These molecules can be new therapeutic targets for slowing the progression of renal diseases or accelerating repair of the injured kidney.
Epithelial-mesenchymal transition (EMT) is a process whereby epithelial cell layers lose polarity and cell-cell contacts and undergo a massive cytoskeleton reorganization involving the rho family and the remodeling of the actin microfilament mesh (Thiery, 2002) . Concurrent with a loss of epithelial cell adhesion and cytoskeletal components, cells undergoing EMT acquire expression of mesenchymal components and manifest a migratory phenotype. This is a fundamental process governing morphogenesis in multicellular organisms during embryonic development. This EMT process, first appreciated by developmental biologists in the early 1980s, is now attracting increasing attention from oncologists and nephrologists, because the process is also reactivated in a variety of diseases, including fibrosis and in the progression of carcinoma. From a therapeutic standpoint, it may be important to reverse EMT in these diseases. EMT is characterized by coordinated changes in cell morphology, associated with the induction of cell motility and the disruption of intercellular junctions. In some cases, cells undergoing EMT start synthesizing extracellular matrix molecules such as fibronectin and certain types of collagen. They may also synthesize proteolytic enzymes involved in matrix degradation that contribute to cell motility and invasiveness. It should be stressed that not all EMTs exhibit the whole range of changes listed here. However, EMT is always associated with cell scattering, defined by the loss of intercellular junctions and acquisition of cell motility. The transformation of mesenchyme to epithelium (MET), the reverse of EMT, also occurs during embryonic development. The differentiation of the metanephric blastema provides a striking example of MET. The cardinal feature of kidney development is the formation of epithelial tubules from nonepithelial mesenchymal cells. This conversion of cell type, MET, is controlled by factors secreted from the ureteric bud (Barasch, 1999; Plisov, 2001) , and these epithelial inducers have been purified from ureteric bud cell lines (Barasch, 1996) . These molecules are endogeneous MET inducers. We have tested some of these [bone morphogenetic protein 7(BMP-7) and lipocalin 2] for their epithelial inducing activities in the context of tumor biology and fibrosis and these results with potential therapeutic applications have been discussed. (J Biol Chem 279:1968 , 2004 . Functional analyses of MUC20 have demonstrated its role as a negative regulator of hepatocyte growth factor (HGF)-induced Grb2-Ras pathway. The C-terminus of MUC20 associates with the multifunctional docking site of Met, preventing Grb2 recruitment to Met and thus attenuating HGF-induced proliferation and matrix metalloproteinase expression (Mol Cell Biol 24:7456, 2004 ). In addition, it has been suggested that the oligomerization of MUC20, caused by its overproduction or some other unknown factor(s), which leads to this association with Met. Interestingly, in human MUC20, the repeat numbers of the extracellular tandem domain, which may have an influence on the oligomerization, showed a divergence, with two to six repeat types in several human cell lines. In this study, to clarify the role of MUC20 in human kidney diseases, we analyzed the expression of MUC20 in kidney tissues of patients with IgAN by in situ hybridization. We also investigated the possible association of the tandem repeat polymorphism of MUC20 with renal survival in 236 patients with histologically proven IgAN. In normal kidneys, the expression of MUC20 was confined to the distal tubules, where Met was colocalized by immunohsitochemistry. In addition, glomerular podocytes and the parietal epithelial cells lining Bowman's capsule demonstrated positive expression of MUC20. In renal tissues of IgAN, up-regulation of MUC20 expression in proximal tubules, as well as in distal tubules, was observed. By Kaplan-Meier analysis, the prognosis of IgAN patients with five or six of tandem repeat of MUC20 (N = 130) was significantly better than those without (N = 106, log-rank, v 2 = 10.51) (P = 0.0012). The tandem repeat polymorphism of MUC20 was an independent risk factor for
